-
2 months ago | 
nature.com | Arthur Mulvey |George Coukos
AbstractThe immune-related adverse events associated with chimeric antigen receptor (CAR)-T cell therapy result in substantial morbidity as well as considerable cost to the health-care system, and can limit the use of these treatments. Current therapeutic strategies to manage immune-related adverse events include interleukin-6 receptor (IL-6R) blockade and corticosteroids.
-
Nov 27, 2024 | 
nature.com | Anais Elewaut |Felix Bayerl |Martin Schönlein |Trung Nguyen |Trung Nguyễn |Francesco Andreatta | +12 more
AbstractThe tumour microenvironment is programmed by cancer cells and substantially influences anti-tumour immune responses1,2. Within the tumour microenvironment, CD8+ T cells undergo full effector differentiation and acquire cytotoxic anti-tumour functions in specialized niches3,4,5,6,7. Although interactions with type 1 conventional dendritic cells have been implicated in this process3,4,5,8,9,10, the underlying cellular players and molecular mechanisms remain incompletely understood.
-
Nov 27, 2024 | nature.com | Anais Elewaut |Felix Bayerl |Martin Schönlein |Trung Nguyen |Trung Nguyễn |Francesco Andreatta | +12 more
AbstractThe tumour microenvironment is programmed by cancer cells and substantially influences anti-tumour immune responses1,2. Within the tumour microenvironment, CD8+ T cells undergo full effector differentiation and acquire cytotoxic anti-tumour functions in specialized niches3,4,5,6,7. Although interactions with type 1 conventional dendritic cells have been implicated in this process3,4,5,8,9,10, the underlying cellular players and molecular mechanisms remain incompletely understood.
-
Oct 11, 2024 | 
nature.com | Florian Huber |Marion Arnaud |Fabrizio Benedetti |Jonathan Thevenet |Johanna Chiffelle |Markus K Muller | +7 more
AbstractThe accurate identification and prioritization of antigenic peptides is crucial for the development of personalized cancer immunotherapies. Publicly available pipelines to predict clinical neoantigens do not allow direct integration of mass spectrometry immunopeptidomics data, which can uncover antigenic peptides derived from various canonical and noncanonical sources.
-
Oct 11, 2024 | nature.com | Florian Huber |Marion Arnaud |Fabrizio Benedetti |Jonathan Thevenet |Johanna Chiffelle |Markus K Muller | +7 more
AbstractThe accurate identification and prioritization of antigenic peptides is crucial for the development of personalized cancer immunotherapies. Publicly available pipelines to predict clinical neoantigens do not allow direct integration of mass spectrometry immunopeptidomics data, which can uncover antigenic peptides derived from various canonical and noncanonical sources.
-
Jul 2, 2024 | 
nature.com | L. Francisco Lorenzo-Martín |Nicolas Broguiere |Jakob Langer |Mikhail Nikolaev |George Coukos
AbstractExisting organoid models fall short of fully capturing the complexity of cancer because they lack sufficient multicellular diversity, tissue-level organization, biological durability and experimental flexibility. Thus, many multifactorial cancer processes, especially those involving the tumor microenvironment, are difficult to study ex vivo.
-
Jun 25, 2024 | 
nature.com | Remy Petremand |Johanna Chiffelle |Marion Arnaud |David Barras |Maria Lozano-Rabella |Raphael Genolet | +6 more
Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-024-02232-0, published online 7 May 2024In the version of the article initially published, there were errors in Extended Data Fig. 5e. One patient was erroneously omitted due to an inaccurate y-axis scale, and in the key “n = 17” has been corrected to “n = 12”. These corrections have been made to the HTML and PDF versions of the article.
-
Jun 25, 2024 | nature.com | Remy Petremand |Johanna Chiffelle |Marion Arnaud |David Barras |Maria Lozano-Rabella |Raphael Genolet | +6 more
Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-024-02232-0, published online 7 May 2024In the version of the article initially published, there were errors in Extended Data Fig. 5e. One patient was erroneously omitted due to an inaccurate y-axis scale, and in the key “n = 17” has been corrected to “n = 12”. These corrections have been made to the HTML and PDF versions of the article.
-
May 7, 2024 | 
nature.com | Remy Petremand |Johanna Chiffelle |Marion Arnaud |David Barras |Maria Lozano-Rabella |Raphael Genolet | +6 more
AbstractA central challenge in developing personalized cancer cell immunotherapy is the identification of tumor-reactive T cell receptors (TCRs).
-
May 7, 2024 | nature.com | Remy Petremand |Johanna Chiffelle |Marion Arnaud |David Barras |Maria Lozano-Rabella |Raphael Genolet | +6 more
AbstractA central challenge in developing personalized cancer cell immunotherapy is the identification of tumor-reactive T cell receptors (TCRs).
